ArticleFrontiers in bioengineering and biotechnology2026
Therapeutic potential of recombinant human collagen XVII in blue light-induced skin photoaging: preserving epidermal-dermal structural integrity and functional homeostasis.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymer-Zn(II) sunscreens for protection against harmful blue ray.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excessive exposure to blue light (BL) contributes to skin photoaging by inducing oxidative stress, inflammation, extracellular matrix degradation, and disruption of epidermal-dermal integrity. Recombinant human type XVII collagen (rhCol17) is a bioactive material with high biocompatibility and reported roles in tissue repair. However, its protective effects against BL-induced photoaging remain unclear. Methods: Results: Conclusion: These findings suggested that rhCol17 protects against BL-induced molecular damage and functional impairment in epidermal and dermal cells, while maintaining epidermal-dermal structural integrity. rhCol17 represents a promising therapeutic strategy for preventing BL-related skin damage and offers preliminary insights for potential clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.